Cost-effectiveness of venlafaxine XL compared with diazepam in the treatment of generalised anxiety disorder in the United Kingdom

被引：12

作者：

Guest J.F. ^{[1
,2
]}

Russ J. ^{[1
]}

Lenox-Smith A. ^{[2
]}

机构：

[1] Wyeth Laboratories, Maidenhead

[2] Catalyst Health Economics Consultants, Northwood

来源：

The European Journal of Health Economics | 2005年 / 6卷 / 2期

关键词：

Anxiety; Costs; Diazepam; National Health Service; Venlafaxine;

D O I：

10.1007/s10198-004-0272-z

中图分类号：

学科分类号：

摘要：

This study used decision modelling to compare the cost-effectiveness of venlafaxine XL (Efexor XL) to that of diazepam to treat non-depressed patients suffering from generalised anxiety disorder (GAD), from the perspective of the United Kingdom's National Health Service (NHS). Starting treatment with venlafaxine XL instead of diazepam significantly increased the expected probability of being in remission by 83% at 6 months (from 16.8% to 30.7%), and the expected probability of relapsing at 6 months was decreased by 79% (from 16.9% to 3.5%). The expected 6-month NHS cost of using venlafaxine XL to treat GAD was estimated to be £353 compared to £311 with diazepam. Hence starting GAD treatment with venlafaxine XL (75 mg per day) instead of diazepam (5 mg three times per day) is clinically more effective and the cost-effective strategy for managing non-depressed patients suffering from GAD in the UK. © Springer Medizin Verlag 2005.

引用

页码：136 / 145

页数：9

共 28 条

[21]

Simon G., Ormel J., Vonkorff M., Et al., Health care costs associated with depressive and anxiety disorders in primary care, Am J Psychiatry, 152, pp. 352-357, (1995)

[22]

Weinstein M.C., Fineberg H.V., Clinical Decision Analysis, pp. 228-265, (1980)

[23]

Rickels K., Schweizer E., The clinical course and long-term management of generalised anxiety disorder, J Clin Psychopharmacol, 51, 10 SUPPL., pp. 101-110, (1990)

[24]

Newman M.G., Recommendations for a cost-offset model of psychotherapy allocation using generalized anxiety disorder as an example, J Consult Clin Psychol, 68, pp. 549-555, (2000)

[25]

Greenberg P.E., Sisitsky T., Kessler R.C., Et al., The economic burden of anxiety disorders in the 1990s, J Clin Psychiatry, 60, pp. 427-435, (1999)

[26]

Candilis P.J., Pollack M.H., The hidden costs of untreated anxiety disorders, Harvard Rev Psychiatry, 5, pp. 40-42, (1997)

[27]

Meltzer H., Gill B., Petticrew M., Et al., The prevalence of psychiatric morbidity among adults living in private households 1996, OPCS Surveys of Psychiatric Morbidity in Great Britain, Report 1, (1996)

[28]

Costa E Silva J.A., The public health impact of anxiety disorders: A WHO perspective, Acta Psychiatr Scand, 98, 393 SUPPL., pp. 2-5, (1998)

← 1 2 3 →